Home › Prostate Cancer › NCT07455058

Water Vapor Ablation for Prostate Cancer: Long-Term Registry

Vanquish® Water Vapor Ablation for PrOstate CanceR: Long-Term Registry

Who can join

All ages · Men

Inclusion Criteria:

* Candidate for Vanquish therapy per physician discretion or participant has completed a company-sponsored Vanquish therapy study.
* Participant is willing and able to provide written informed consent.

Exclusion Criteria:

* Contraindications per the Vanquish IFU
* Previously participated in VAPOR 2 study and is not planning to receive further Vanquish therapy.

About the study

The purpose of the registry is to evaluate real-world safety, efficacy, and patient reported outcomes among participants receiving Vanquish Water Vapor Ablation System therapy (Vanquish Therapy). This includes longitudinal assessment of patients who have received or will receive the therapy one or multiple times as part of routine clinical care and encompasses those who completed a company-sponsored Vanquish therapy study (as applicable).

What is being tested

• Vanquish Therapy (device)

Sponsor: Francis Medical Inc. · Participants: 2,500 · Started: Jun 5, 2026

Contact the study team

• Sydney Cartie · Phone: 6122866855
• Garrett Grenier · Phone: 763-453-9404

Official record on ClinicalTrials.gov — NCT07455058

Locations in the U.S.

Conditions

• Prostate Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.